Board of Directors

"Operational excellence and biological insight ensure that breakthrough airway innovations transition seamlessly from design into trusted, sustainable clinical practice worldwide."

Talha Nasir serves as Chief Operating Officer (COO) across TALRIA LIMITED DMCC’s medical and veterinary portfolios. With a scientific foundation in marine biology and environmental sciences, he directs operational execution, regulatory compliance, quality management, and sustainable biomedical development. Working closely with international manufacturing partners and clinical research teams, he oversees operational strategy to ensure every generation of supraglottic device complies strictly with international directives (MDR 2017/745, ISO 13485, and US FDA requirements), uniting rigorous biological insight with high-precision global operations.

"Breakthrough healthcare technology only achieves its true purpose when made accessible to operating theaters and paramedics on every continent."

Mr. Tuaha Nasir spearheads international business development, strategic licensing alliances, and commercial channel expansion for TALRIA LIMITED DMCC. Managing corporate relationships with multinational medical device distributors, contract manufacturing partners, and clinical purchasing syndicates, Tuaha has been instrumental in scaling the commercial footprint of Dr. Nasir’s airway technologies across Europe, North America, the Middle East, and Asia. He also directs cross-border trade operations and serves as a director in family commercial enterprises and charitable initiatives including Light4Life.

"When surgeons and veterinarians experience first-hand how fast and safe anatomical gel-seals are, standard clinical protocols change permanently."

Mr. Adam Nasir leads market penetration strategies, clinical education initiatives, and veterinary institutional integration for TALRIA LIMITED DMCC. He focuses on building long-term alliances with veterinary teaching hospitals, university anaesthesia departments, private veterinary clinic groups, and military medical academies. Adam’s market-building expertise drives rapid clinical adoption by demonstrating how the transition from cuffed endotracheal tubes to non-inflatable supraglottic airways dramatically lowers patient morbidity and accelerates surgical turnover.

"Sound fiscal management and robust corporate governance within DMCC provide the resilient platform required to protect and monetize world-class biomedical IP."

Mr. Danyal Nasir directs corporate finance, treasury operations, IP valuation, and fiscal governance for TALRIA LIMITED DMCC. Overseeing the enterprise’s financial architecture from the Dubai Multi Commodities Centre (DMCC) headquarters, Danyal coordinates cross-border royalty streams, investment allocation for clinical trials, tax-efficient IP asset stewardship, and compliance with UAE Free Zone and international statutory accounting standards. His stewardship provides the fiscal backbone that fuels continuous R&D and global patent protection.

"By aligning disciplined corporate compliance with visionary medical R&D, we transform advanced biomedical intellectual property into scalable global value."

Mr. Touseef Akhtar directs strategic operations, commercial development, and R&D pipelines for TALRIA LIMITED DMCC from the company's headquarters in the Dubai Multi Commodities Centre (DMCC). Bringing extensive multi-sector experience in Pharma, healthcare and medical device innovation, Mr. Akhtar leads the enterprise's research initiatives, product engineering roadmaps, and global clinical validation strategies. Working in alignment with the firm's fiscal and corporate governance framework—overseen by Company Directors —Mr. Akhtar coordinates cross-border technology transfers, regulatory compliance protocols, and commercialization pathways for advanced medical technologies. His leadership bridges scientific innovation with rigorous operational execution, driving the continuous development and global market introduction of proprietary medical devices.